NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
🟢 Neurosense Therapeutics is trading 6.37% up today as XBI gains 2.06%
Neurosense Therapeutics is trading 6.37% up now at $0.40, with the advance best explained by broader biotech-sector strength as XBI rises 2.06%. - No...
🟢 Neurosense Therapeutics is trading 5.16% up in pre-market with no confirmed fresh catalyst
Neurosense Therapeutics is trading 5.16% up in pre-market at $0.40, after closing at $0.38 on August 21, 2026, with no confirmed fresh catalyst identified. -...
🟢 Neurosense Therapeutics is trading 11.30% up today after August 20 selloff
Neurosense Therapeutics is trading 11.30% up at $0.39 after rebounding from its August 20 close of $0.35. - Shares fell 11.96% on August 20. - No new...
🔴 Neurosense Therapeutics is trading 12.04% down today amid delays securing Phase 3 financing
Neurosense Therapeutics is trading 12.04% down now at $0.35 after investors continued reacting to disclosed delays in securing financing for the Phase 3...
🔴 Neurosense Therapeutics is trading 7.06% down today amid concerns over Phase 3 funding delays
Neurosense Therapeutics is trading at $0.37 (-7.06%) amid broader biotech and market weakness; no confirmed August 20, 2026 company-specific announcement...
🔴 Neurosense Therapeutics is trading 10.97% down today; no specific catalyst confirmed
Neurosense Therapeutics is trading at $0.34, down -10.97%, with no specific catalyst confirmed. • No credible company-specific announcement dated August 19,...
🟢 Neurosense Therapeutics rises 7.3% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Neurosense Therapeutics is trading 6.81% up in pre-market following continued after-hours strength despite no confirmed company-specific catalyst
Neurosense Therapeutics is trading now 6.81% up at $0.41 after closing at $0.38 on August 18, 2026, following continued after-hours strength without a...
🟢 Neurosense Therapeutics is trading 12% up in after-hours trading with no confirmed catalyst
Neurosense Therapeutics is trading at $0.43, up 12.02% in after-hours trading, with no confirmed company-specific catalyst. - It closed at $0.38 on August 18,...
🟢 Neurosense Therapeutics is trading 5% up in after-hours trading without a confirmed company catalyst
Neurosense Therapeutics is trading 5% up in after-hours trading at $0.40 after the August 18, 2026 close of $0.38, reflecting limited positioning rather than a...
🔴 Neurosense Therapeutics is trading 11% down today amid broad risk-off selling
Neurosense Therapeutics is trading 11% down at $0.39 amid broad risk-off selling on August 18, 2026. - Nasdaq Composite and S&P 500 fell as technology shares...
🔴 Neurosense Therapeutics is trading 5% down today amid a broader market pullback
Neurosense Therapeutics is trading 5% down at $0.41 amid a broader market pullback. - The S&P 500 was down 0.61% and the Nasdaq Composite was down 1.37% on...
🔴 Neurosense Therapeutics is trading 5% down today with no new company-specific catalyst identified
Neurosense Therapeutics is trading 5.10% down now at $0.43 after no new company-specific catalyst was identified on August 17, 2026. - The latest material...
🟢 Neurosense Therapeutics is trading 5.94% up today — catalyst remains unclear
Neurosense Therapeutics is trading 5.94% up at $0.48, with the catalyst unclear on August 17, 2026. - No new company-specific announcement has been...
🟢 Neurosense Therapeutics is trading 11.59% up in pre-market with no new company-specific announcement identified
Neurosense Therapeutics is trading 11.59% up at $0.51 in pre-market, with no new company-specific announcement identified for August 17, 2026, and the catalyst...
🟢 Neurosense Therapeutics is trading 6.44% up in after-hours trading
Neurosense Therapeutics is trading 6.44% up at $0.48 after no new company-specific announcement was identified for August 14, 2026. - An August 13 CEO letter...
NeuroSense's ALS Drug Funding Hits a Wall — Can a Sub-Dollar Stock Survive Nasdaq's Patience Running Out?
Shares of NeuroSense Therapeutics shifted sharply this week as a CEO letter dated August 13, 2026, laid bare the company's struggle to fund its most important...
🟢 Neurosense Therapeutics is trading 8.46% up today in after-hours trading after PARAGON ALS funding delays
Neurosense Therapeutics is trading 8.46% up at $0.48 after its August 13, 2026 CEO letter detailed delays securing funding for the Phase 3 PARAGON ALS study. -...
🔴 Neurosense Therapeutics is trading 5% down today after CEO letter highlighted funding delays
Neurosense Therapeutics is trading 5% down at $0.45 after its August 13, 2026 CEO letter highlighted delays securing funding for the Phase 3 PARAGON ALS...
🟢 Neurosense Therapeutics is trading 5% up in pre-market
Neurosense Therapeutics is trading at $0.49, up +5.08% in pre-market; the catalyst remains unclear and may reflect low-priced biotech trading activity. - No...